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Abstract
Methemoglobinemia and sulfhemoglobinemia are potentially life-threatening blood dis-
orders characterized by similar symptoms and markedly distinct treatment procedures. In
this thesis, we investigate the causal relationship between these disorders and the onset
of cyanosis (purple or bluish skin coloration). More specifically, we perform controlled
experiments to elicit cyanotic appearances resulting from different severity levels of these
disorders and varying physiological conditions. We note that such experiments cannot
be induced in living subjects without posing risks to their health. Accordingly, we have
resorted to an in silico experimental approach supported by biophysical data reported in
the biomedical literature. Besides bringing new insights about cyanotic chromatic varia-
tions elicited by methemoglobinemia and sulfhemoglobinemia, our investigation provides
the basis for the proposition of a cost-effective protocol for the noninvasive detection and
differentiation of these disorders. Our experimental results indicate that its sensitivity
range exceeds the range of similar technologies, which are in general associated with high
operational costs. We believe that these aspects make the proposed protocol particularly
suitable for incorporation into noninvasive disease screening/diagnostic systems, particu-
larly those deployed at the point of care of medical settings with limited access to laboratory
resources.
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Chapter 1
Introduction
A number of medical conditions, including arterial thrombosis and heart failure, can have
as one of their most noticeable initial symptoms cyanosis [10, 62, 17], a characteristic
purple or bluish coloration of the mucosal membranes, nail beds and skin. In its early
stages, it can also appear as a grey cutaneous discoloration [38]. Although cyanosis is
often elicited by the presence of high levels of deoxygenated hemoglobin in blood-perfused
cutaneous tissues [61, 35], it can also be prompted by the presence of abnormal amounts of
dysfunctional forms of hemoglobin (which are characterized by not having the capability to
bind reversibly with oxygen [31, 44]) in these tissues [17]. In the latter case, cyanosis may
indicate the occurrence of two potentially life-threatening dyshemoglobinemia disorders,
namely methemoblobinemia and sulfhemoglobinemia [36, 41, 44]. These disorders, in turn,
are associated with excessive amounts of dysfunctional forms of hemoglobin known as
methemoglobin (MetHb) and sulfhemoglobin (SHb), respectively, in the blood stream [30,
59]. Under normal physiological conditions, the blood circulating in the body transports
primarily the functional forms of hemoglobin (oxygenated and deoxygenated).
We note that another form of dysfunctional hemoglobin, known as carboxyhemoglobin
(COHb), can also be found in blood-perfused cutaneous tissues [82]. In fact, carbon monox-
ide poisoning may result in high levels of COHb [50]. Above a 40% level, the patient’s skin
may start to depict a cherry red coloration [43]. Beyond a 60% level, it may lead to her/his
death [43, 50]. Since COHb is not associated with the onset of cyanosis and its presence
in the blood stream can be detected and differentiated from other forms of hemoglobin in
a relatively straightforward manner [50], it is not further examined in this work.
Both methemoglobinemia and sulfhemoglobinemia can be caused by similar chemical
agents and be characterized by similar symptoms, which worsen as the MetHb and SHb
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Figure 1.1: Photograph showing hands depicting a cyanotic appearance [42], notably on the finger-
tips. It can be a symptom of a number of medical conditions, from a disorder of the blood vessels
(as it is the case for this patient) known as Raynaud’s phenomenon [42] to disorders affecting the
blood’s capability to transport oxygen known as methemoglobinemia and sulfhemoglobinemia.
Reprinted by permission from Springer.
levels increase. In the case of methemoglobinemia, a high mortality rate is often observed
when the MetHb level is superior to 70% of the total hemoglobin content [44]. In the case of
sulfhemoglobinemia, end-organ damage and death can occur when the SHb level is superior
to 60% of the total hemoglobin content [38, 36]. In most cases, methemoglobinemia is
reversible through the administration of a substance known as methylene blue [40]. There
have been reports, however, of unusual cases in which it did not respond to this treatment
[80, 73]. Sulfhemoglobinemia, on the other hand, is not reversible and its management
often requires blood transfusions that may pose additional risks to the patient [38, 12].
Thus, if sulfhemoglobinemia is misdiagnosed as methemoglobinemia, the use of methylene
blue as antidote will be ineffective [28]. In addition, it may lead to other medical problems
such as renal failure [99].
These aspects highlight the importance of the early detection and differentiation of these
dyshemoglobinemia disorders. Although devices like co-oximeters and blood gas analysers
can be employed, to detect the abnormal presence of MetHb and SHb in blood samples
[39, 36], there are two issues that need to be examined when considering this approach,
namely cost and effectiveness. With respect to cost limitations, it is worth noting that
these detection tests are not performed routinely in most intensive care units and need to
be ordered specifically [39]. Hence, one can expect their availability to be even more limited
in low-resource clinical settings. With respect to effectiveness, it has been reported that the
readings provided by these devices can diverge significantly from actual MetHb and SHb
2
values [63, 28, 36]. Moreover, available co-oximeters often have difficulties to differentiate
between SHb and MetHb [12, 28], and most blood gas analysers do not report SHb levels
[28, 36]. Although other technologies, such as the use of optoacoustic sensors [74] or
dedicated spectral sensors [91], have been proposed to detect the presence of dysfunctional
hemoglobins in the blood stream, they also depend on the collection of blood samples.
This invasive procedure is not only potentially painful, but it may also pose additional
risks to the patient. These may include, for example, a significant blood loss if multiple
blood samplings are required. Such a situation may be particularly worrisome in the case
of preterm infants [53].
Ideally, one would like to employ noninvasive and low-cost approaches in the detec-
tion and differentiation of methemoglobinemia and sulfhemoglobinemia, particularly at
the point of care. These include the visual assessment of cyanosis [12]. However, the
extent to which this assessment can contribute for the effective detection and differenti-
ation of these disorders remains an open problem. This can be largely attributed to the
relatively limited amount of experimental information about the impact of different levels
of MetHb and SHb on skin appearance available in the biomedical literature. Oftentimes
works relating cyanosis to abnormal levels of MetHb and SHb refer to in vitro experiments
performed considering only a handful of test cases [36]. In fact, to date, the small number of
reported cases of methemoglobinemia and sulfhemoglobinemia and the consequent scarcity
of supporting chromatic and spectral data associated with the onset of cyanotic skin ap-
pearances represent major obstacles for advances in this area [12, 36, 63, 39]. Besides these
data limitations, controlled in vivo quantitative investigations of cyanosis caused by dyshe-
moglobinemia disorders would involve a relatively large number of biophysical parameters
that would need to be kept fixed during the experiments. This would represent another
technical challenge.
Nowadays, controlled in silico experiments performed through predictive computer sim-
ulations are being extensively employed in biomedical research [93, 95]. In the specific case
of light interactions with human skin, the information derived from in silico experiments
contributes not only to the elucidation of scientific questions about these phenomena, but
also to the development of more effective procedures aimed at the noninvasive diagnosis
and treatment of diseases [88, 12]. Besides its flexibility and the absence of the health-
related risks normally associated with in vivo experiments, such an investigation approach
mitigates the impact of the data and technical constraints mentioned above. For example,
as many test cases as necessary can be carried out in silico, i.e., they are not bound by
a limited set of experimental conditions and on the availability of living subjects. In ad-
dition, specific biophysical parameters of interest can be varied while the remaining ones
can be treated as constants without incurring in significant logistic overhead.
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For these reasons, we also resorted to an in silico approach in the work described in this
thesis. More precisely, we performed controlled in silico experiments to closely investigate
the impact of key biophysical factors on the onset of cyanosis elicited by methemoglobine-
mia and sulfhemoglobinemia. Our findings, in addition to broadening the current knowl-
edge about this complex causal relationship, enabled us to propose a cost-effective protocol
for the noninvasive detection and differentiation of these life-threatening disorders. The
proposed protocol is expected to outperform technologies currently used in these tasks, not
only in terms of effectiveness to cost ratio, but also with respect to sensitivity range.
The remainder of this thesis, whose main contents have also been made available in
a journal publication [7], is organized as follows. In Chapter 2 we concisely review bio-
physical concepts and terminology relevant for this work. In Chapter 3, we describe the
methods and data employed in this investigation. In Chapter 4, we present our findings,
discuss their practical implications and propose a protocol for the noninvasive detection
and differentiation of methemoglobinemia and sulfhemoglobinemia. Finally, in Chapter 5,
we conclude the thesis and comment on future prospects in this area.
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Chapter 2
Biophysical Background
In this chapter, we review fundamental biophysical information associated with our in-
vestigation. We begin by concisely describing the main characteristics of human skin in
Section 2.1. We then outline the main optical factors responsible for cyanotic skin appear-
ances in Section 2.2. Finally, in Section 2.3, we introduce radiometric concepts employed
in our in silico experiments described in Chapter 2.
2.1 Skin Overview
Human skin is usually considered to be composed of three distinct tissues (Fig. 2.1), namely
the stratum corneum, the epidermis and the dermis [101]. The stratum corneum and the
epidermal layers (stratum granulosum, stratum spinosum and stratum basale, from the
outermost to the innermost) are primarily composed of stratified cells [27]. In thick regions
of the skin, such as the soles, a clear epidermal layer, known as stratum lucidum, can be
found immediately below the stratum corneum [27]. The dermis forms the bulk of the full
thickness of skin (Fig. 2.1). It can be divided into the papillary dermis and reticular dermis
[6]. Compared to the reticular dermis, the papillary dermis is relatively thin and contains
smaller-sized structural fibers. The dermis also contains a network of blood vessels, with
wider vessels being located in the reticular dermis [11].
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Stratum Granulosum
Stratum Spinosum
Stratum Basale
Papillary Dermis
Reticular Dermis
Epidermis
Stratum Corneum
Dermis
Figure 2.1: Diagram depicting the spatial organization of the cutaneous tissues (from the outer-
most to the innermost) and their main layers.
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Light impinging on the skin surface can be reflected back to the environment or trans-
mitted into its internal tissues. Once light is transmitted into the skin tissues, it can be
further attenuated by their constituent materials, either through absorption or scattering
events [17]. Relevant absorbing materials acting in the ultraviolet (UV) and visible regions
of the light spectrum are situated within the stratum corneum and epidermis. Examples
include include DNA, keratin, urocanic acid and melanin. The latter may occur in two
forms within human skin: the brown-black eumelanin and the yellow-red pheomelanin
[23]. Blood-borne pigments (e.g., hemoglobin, bilirubin and beta-carotene) found in the
dermal layers are also relevant absorbers in the visible domain [105]. Water and lipids
found throughout the skin dominate the absorption of light in the infrared region of the
light spectrum [11].
Within the cutaneous tissues, light is mostly scattered by heterogeneous structures, such
as cells, organelles, fibers and fibrils [6]. Among these structures, the melanin-containing
organelles, known as melanosomes, have a central role in the attenuation of UV and visible
light travelling within the cutanueous tissues [55]. The dermal layers contain dense connec-
tive tissue. Light traversing the papillary dermis may be subjected to Rayleigh scattering
(which has a stronger effect at the “blue” end (400 to 500 nm) of the visible spectrum)
caused by the presence of collagen fibrils [90]. As light penetrates deeper into the more
turbid reticular dermis, it becomes progressively diffuse [49].
Eventually, the light traversing the dermis may reach the hypodermis, a subcutaneous
tissue that consists mostly of white fat cells that contain lipid droplets [3]. Various studies
have indicated that the majority of the visible light that reaches this tissue is likely to be
scattered by these droplets and remitted into the cutaneous tissues, notably the reticular
dermis.
2.2 Cyanosis Optics Overview
A hemoglobin molecule encapsulates four heme (an iron-containing compound) porphyrin
rings (linked group of organic compounds with a central metal atom), each with a centrally
localized iron atom [12]. These iron atoms are capable of binding with oxygen when they are
in a ferrous state. However, if an iron atom is oxidized (loses an electron) to a ferric state, it
can no longer bind to oxygen. The functional forms of hemoglobin, namely oxyhemoglobin
and deoxyhemoglobin, stored in the red blood cells (RBCs) can bind oxygen reversibly,
However, dysfunctional forms of hemoglobin also stored in the RBCs, such as MetHB and
SHb, do not have this capability [12]. While MetHb corresponds to a reversible type of
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oxidized hemoglobin, SHb corresponds to an irreversible type (it lasts the lifetime of the
RBC) that results from the incorporation of a sulfur atom in its porphyrin ring [103, 38].
From an optics perspective, cyanotic chromatic attributes have been often associated
with the light absorption properties of the hemoglobins, with several authors incorrectly
attributing the typical cyanotic bluish hue to an allegedly blue appearance of deoxygenated
blood (e.g., [62, 9]). However, one has to consider the fact that the hemoglobins are strong
absorbers in the blue end of the visible spectrum (Fig. 2.2). In addition, light traveling
within the skin tissues may also be strongly attenuated by the melanins. Thus, arterial
blood appears bright red, while venous blood appears dark red, almost black, but not blue
[54, 104]. In the case of arterial blood containing high amounts of MetHB or SHb, it would
appear brown or green [99, 103], respectively. Hence, the purple or bluish coloration of
cyanotic skin must be also associated with other light attenuation phenomena besides the
absorption by pigments like the hemoglobins. It has been recently demonstrated [17, 18]
that Rayleigh scattering taking place in the papillary dermis can play a pivotal role in the
onset of typical cyanotic purple and bluish coloration.
(a) (b)
Figure 2.2: Absorption spectra of the hemoglobins. (a) Molar extinction coefficient curves for
the functional hemoglobins [76]. (b) Molar extinction coefficient curves for the dysfunctional
hemoglobins [77, 82, 103].
2.3 Relevant Radiometric Concepts
Variations in the spectral distribution of the light propagated by a material, like a skin
specimen, affect its appearance characteristics, particularly its hue (the attribute of color
perception by means of which an object is judged to be red, yellow, green, blue, purple
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and so forth [15]). Such variations, in turn, can be quantified in terms of reflectance. This
radiometric quantity, denoted by ρ(λ), represents the fraction of light at wavelength λ
impinging on a material that is reflected by it. In general, reflectance measurements are
performed using a spectrophotometer [47].
Alternatively, reflectance can be defined as the spectral power distribution of the re-
flected light, i.e., the ratio of the reflected radiant power, Φr, to the incident radiant power,
Φi [15]:
ρ(λ) =
Φr(λ)
Φi(λ)
. (2.1)
There are nine different representations of reflectance. These representations depend
on the incident and propagated (collected) light geometries, which are designated as direc-
tional, conical and hemispherical [67]. The directional geometry designates a differential
solid angle dω about a single direction ψ (represented by a pair of spherical coordinates
θ and φ). The conical geometry designates a solid angle ω of any configuration (e.g., a
right circular cone). Finally, a hemispherical geometry designates a full hemispherical solid
angle ω = 2pi [15].
Considering a ray optics stochastic simulation framework, like the one employed in
this research (Chapter 3), in which n rays are shot towards a specimen from a direction
represented by dωi and at a given wavelength λ, we can assume that each ray carries the
same amount of radiant power, denoted by Φray. If the total radiant power to be shot is
Φi, then the radiant power carried by each ray is given by [15]:
Φray(λ) =
Φi(λ)
n
. (2.2)
Hence, according to Equation 2.1, if nr rays are reflected towards the upper hemisphere
Ωr, the directional-hemispherical reflectance of a specimen with respect to a wavelength λ
can be quantified as [16]:
ρ(λ, dωi,Ωr) =
nr
n
. (2.3)
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Chapter 3
Investigation Framework
During the investigation described in this thesis, we performed controlled in silico experi-
ments considering distinct severity levels of methemoglobinemia and sulfhemoglobinemia.
More specifically, we used a predictive model of light and skin interactions (Section 3.1)
and specimen characterization data a variable in the biomedical literature (Section 3.2)
to compute directional-hemispherical reflectance curves for a cutaneous site considering
variations in its dysfunctional hemoglobin (MetHb and SHb) levels and blood content. We
then generate skin swatches (Section 3.3) to analyse the visual differences between the
cyanotic appearances elicited by these disorders. These components of our investigation
framework are described next.
3.1 In Silico Experimental Set-up
The model of light and skin interactions employed in our controlled in silico experi-
ments, known as HyLIoS (Hyperspectral Light Impingement on Skin) [25], employs a
first-principles simulation approach. Accordingly, it accounts for all main light absorbers
(keratin, DNA, uranic acid, melanins, functional and dysfunctional hemoglobins, beta-
carotene, bilirubin, lipids and water) and scatterers (cells, melanosomes, fibers and fibrils)
acting within the cutaneous tissues [11]. These correspond to the stratum corneum, the
melanin-containing epidermis (subdivided into three main layers, the stratum granulosum,
the stratum spinosum and the stratum basale) and the blood-perfused dermis (subdivided
into the thin papillary layer and the dominant reticular layer (Fig. 2.1)).
Within the HyLIoS’ geometrical-optics formulation, a ray interacting with a given skin
specimen can be associated with any wavelength within a spectral region of interest. For
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consistency, we considered a spectral resolution of 5 nm in all curves depicted in this work,
which were computed using a virtual spectrophotometer [16]. In their computation, we
employed 106 sample rays and, unless otherwise stated, considered an angle of incidence
equal to 15◦.
Clearly, the reliability of an in silico experimental framework is directly associated
with the predictive capabilities of the computer model used in the simulations. Hence,
it is important to note that HyLIoS was extensively evaluated through qualitative and
quantitative comparisons of its outcomes with actual measured data [25]. Since then,
it has been effectively employed in a number of related biomedical investigations (e.g.,
[13, 17, 18, 90]).
For conciseness, we refer the reader interested in the full description of the HyLIoS
model to the publications in which it was originally presented [24, 25]. Moreover, for
the readers interested in the full reproduction of our in silico experimental results, we
note that HyLIoS is available online [66] via a model distribution system [14] along with
the supporting data (e.g., refractive index and extinction coefficient curves of the light
absorbers) [70] used in our investigation. This system enables researchers to specify the
values to be assigned to the measurement variables (e.g., angle of incidence and spectral
range) and specimen characterization parameters (Tables 3.1, 3.2 and 3.3) using a web
interface [66], and receive customized simulation results.
3.2 Specimen Characterization Data
We have elected the palmar fingertip as the testing site for our in silico experiments for the
following reasons. This hypopigmented site is characterized by a reduced melanin content
(more than fivefold lower than in the nonpalmoplantar regions [100]), which minimizes
the masking effects of melanin on the visual assessment of cyanotic appearances [39, 18].
In addition, it is also characterized by an increased blood content [89, 18], making their
spectral responses, and consequently, their cyanotic chromatic attributes more susceptible
to changes in the contents of blood-borne pigments like MetHb and SHb. It is worth noting
that the noninvasive measurement of blood related properties (e.g., oxygen saturation levels
measured using a pulse oximeter [31]) is usually performed at this site, which has also been
considered in previous investigations involving peripheral cyanosis [17, 18].
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Table 3.1: Parameters employed in the characterization of a palmar fingertip. The acronyms
SC, SG, SS, SB, PD and RD refer to the skin layers considered by HyLIoS: stratum corneum,
stratum granulosum, stratum spinosum, stratum basale, papillary dermis and reticular dermis,
respectively.
Parameter Value Ref.
Ratio of Skin Surface Folds 0.1 [85][60]
SC Thickness (cm) 0.013 [3][2][75][78]
SG Thickness (cm) 0.0123 [97]
SS Thickness(cm) 0.0123 [97]
SB Thickness (cm) 0.0123 [97]
PD Thickness (cm) 0.02 [79]
RD Thickness (cm) 0.125 [5]
SC Melanosome Content (%) 0.0 [55][58]
SG Melanosome Content (%) 0.0 [55][58]
SS Melanosome Content (%) 0.0 [55][58]
SB Melanosome Content (%) 0.15 [103]
SC Colloidal Melanin Content (%) 0.06 [55][4][72]
SG Colloidal Melanin Content (%) 0.06 [55][4][72]
SS Colloidal Melanin Content (%) 0.06 [55][4][72]
SB Colloidal Melanin Content (%) 0.06 [103]
SB Melanosome Dimensions (µm× µm) 0.41× 0.17 [71]
Melanosome Eumelanin Concentration (g/L) 32.0 [87][45]
Melanosome Pheomelanin Concentration (g/L) 2.0 [87][45]
PD Blood Content (%) 0.5 [21]
RD Blood Content (%) 2.0 [68]
Dermal Oxygenated Hemoglobin Fraction (%) 90.0 [69]
Functional Hemoglobin Concentration in Blood (g/L) 147.0 [102]
MetHb Concentration in Blood (g/L) 1.5 [12]
COHb in Blood (g/L) 1.5 [12]
SHb Concentration in Blood (g/L) 0.0 [12]
Blood Bilirubin Concentration (g/L) 0.003 [107]
SC Beta-Carotene Concentration (g/L) 2.1E-4 [57]
Epidermis Beta-Carotene Concentration (g/L) 2.1E-4 [57]
Blood Beta-Carotene Concentration (g/L) 7.0E-5 [57]
SC Water Content (%) 35.0 [1][64]
Epidermis Water Content (%) 60.0 [1] [94]
Continues on the following page ...
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Table 3.1 – Continuation
Parameter Value Ref.
PD Water Content (%) 75.0 [1] [94]
RD Water Content (%) 75.0 [1] [94]
SC Lipid Content (%) 20.0 [98]
Epidermis Lipid Content (%) 15.1 [1][83][22]
PD Lipid Content (%) 17.33 [1][83][22]
RD Lipid Content (%) 17.33 [1][83][22]
SC Keratin Content (%) 65.0 [33][81][34]
SC Urocanic Acid Density (mol/L) 0.01 [105]
Skin DNA Density (g/L) 0.185 [1][92][32]
SC Refractive Index 1.55 [86][29]
Epidermis Refractive Index 1.4 [88][60]
PD Refractive Index 1.39 [86][49]
RD Refractive Index 1.41 [86][49]
Melanin Refractive Index 1.7 [19]
PD Scatterers Refractive Index 1.5 [96]
Radius of PD Scatterers (nm) 40.0 [68]
PD Fraction Occupied by Scatterers (%) 22.0 [48]
Without loss of generality, we have characterized a palmar fingertip site in its normal
(baseline) state using the dataset presented in Table 3.1. The selection of values for the
parameters included in this dataset was based on physiologically valid ranges provided
in related references, which are also listed in Table 3.1. We note that, for some of these
parameters, the determination of physiologically valid ranges involved the use of multiple
references.
Using HyLIoS and the dataset provided in Table 3.1, we then computed the baseline
reflectance curve (Fig. 3.1 (b)) used as reference in our experiments. Subsequently, we
computed reflectance curves associated with distinct severity levels of methemoglobine-
mia and sulfhemoglobinemia using modified versions of this dataset. These modified
versions correspond to the dataset provided in Table 3.1, with the MetHb, SHb and
functional hemoglobin (Hb) concentrations in blood replaced by the values provided in
Tables 3.2 and 3.3. We remark that these dyshemoglobinemia disorders are associated with
the abnormal presence of MetHb and SHb in the blood stream. Hence, in our experiments,
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we also took into account variations in the blood content of the reticular dermis (denoted
by vrdblood) from 2 to 15% [21].
In our baseline case, we considered COHb, MetHb and SHb concentrations in blood
equal to 1.5, 1.5 and 0 g/L. It is worth noting that this selection of values was performed
considering that, in normal physiological states, only small traces (< 2%) of COHb and
MetHb are found in human blood [44, 26, 103], while SHb is absent [103, 38].
Table 3.2: MetHb and functional hemoglobin concentrations (in g/L) used in the simulation of
distinct levels (represented by percentages of MetHb with respect to total hemoglobin content)
of methemoglobinemia severity.
10% 20% 30% 40% 50% 60% 70% 80%
MetHb 15 30 45 60 75 90 105 120
Functional Hemoglobins 133.5 118.5 103.5 88.5 73.5 58.5 43.5 28.5
Table 3.3: SHb and functional hemoglobin concentrations (in g/L) used in the simulation of
distinct levels (represented by percentages of SHb with respect to total hemoglobin content) of
sulfhemoglobinemia severity.
10% 20% 30% 40% 50% 60% 70% 80%
SHb 15 30 45 60 75 90 105 120
Functional Hemoglobins 132 117 102 87 72 57 42 27
3.3 Swatch Generation and Analysis
Our investigation also included the generation of skin swatches, henceforth referred to as
MetHb and SHb swatches, to enable the analysis of the visual impact of distinct severity
levels of methemoglobinemia and sulfhemoglobinemia, respectively, on cyanotic appear-
ances elicited by these disorders. The swatches’ chromatic attributes were obtained from
the convolution of a selected illuminant’s relative spectral power distribution, the modeled
reflectance data and the broad spectral response of the human photoreceptors [46]. This
last step was performed by employing a standard CIEXYZ to RGB color system conver-
sion procedure [15, 56] and considering the CIE standard D65 (daylight) illuminant [46]
(Fig. 3.1(a)). For the reader interested in reproducing this process, the corrresponding
Matlab [8] code is provided in Appendix E. After computing the chromatic attributes of
a swatch, we applied a greyscale texture (Fig. 3.1(c)) to make its depiction more realistic.
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For comparison purposes, the skin swatch obtained using the baseline reflectance curve
(Fig. 3.1(b)) computed for the selected specimen is presented in (Fig. 3.1(d)).
Besides visual inspection, we also employed a device-independent CIE-based metric
to compare skin swatches associated with distinct severity levels of methemoglobinemia
and sulfhemoglobinemia. More specifically, we computed the CIELAB differences between
pairs of swatches using the following formula [84]:
∆E∗ab =
√
dL
2 + da
2 + db
2, (3.1)
where dL, da and db represent the differences L
∗
1 − L∗2, a∗1 − a∗2 and b∗1 − b∗2, respectively,
in which L∗, a∗ and b∗ correspond to the CIELAB color space dimensions. These are
calculated for the modeled chromatic attributes associated with the compared swatches
(indicated by the subscripts 1 and 2, respectively). Again, we performed these calculations
using standard formulas employed in colorimetry [20, 56] and considering the CIE standard
D65 illuminant [46]. As before, for the reader interested in reproducing these calculations,
the corresponding Matlab code is provided in Appendix E.
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(a) (b)
(c) (d)
Figure 3.1: Components of the convolution process employed to generate a skin swatch depicting a
palmar fingertip in its normal (baseline) state. (a) The relative spectral power distribution of the
CIE standard D65 illuminant. (b) The baseline reflectance curve computed using the parameter
values depicted in Table 3.1. (c) Greyscale texture of a palmar fingertip. (d) Resulting swatch.
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Chapter 4
Investigation Findings
In this chapter, we present our findings and discuss their practical implications for the
differentiation and monitoring of methemoglobinemia and sulfhemoglobinemia. We start
with the examination of the reflectance curves obtained in our in silico experiments, hence-
forth referred to as dysfunctional (MetHb or SHb) reflectance curves. This is followed by
a visual inspection and analysis of appearance changes resulting from distinct severity lev-
els of methemoglobinemia and sulfhemoglobinemia. Building on the observations derived
from our in silico experimental results, we then outline a cost-effective protocol for the
noninvasive detection and differentiation of methemoglobinemia and sulfhemoglobinemia.
4.1 Methemoglobinemia and Sulfhemoglobinemia
Spectral Responses
Initially, we performed experiments considering the blood content of the reticular dermis
(vrdblood) equal to 2%. The results of these experiments are depicted in the graphs presented
in Fig. 4.1. By examining these graphs, one can observe that the deviation of the dysfunc-
tional reflectance curves from the baseline reflectance curve (Fig. 3.1 (b)) becomes more
pronounced as the presence of MetHb and SHb increases, albeit with distinct deviation
patterns being observed for the MetHb and SHb curves. More precisely, in the “blue” re-
gion (400 to 500 nm) of the visible light spectrum, one can observe a decrease in the MetHb
curves and an increase in the SHb curves. In the “green” region (500 to 600 nm), one can
observe an increase in both sets of curves. This increase, however, is more prominent for
the MetHb curves. As a consequence, these curves show a more pronounced deviation
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from the characteristic “w” shape (associated with a dominant presence of oxygenated
hemoglobin [104]) discerned in the baseline reflectance curve (Fig. 3.1 (b)). Finally, in the
“red” region (600 to 700 nm), one can observe a decrease in both sets of curves. This
decrease, however, is more prominent for the SHb curves.
Afterwards, we performed experiments considering vrdblood equal to 5, 10 and 15%, whose
results are presented in Fig. 4.2, Fig. 4.3, and Fig. 4.4, respectively. Although the same
deviation patterns noted for the 2% case can be observed for the 5, 10 and 15% cases,
the differences between the MetHb and SHb curves become smaller as vrdblood increases,
particularly in the “blue” and “green” regions. In the “red” region, while both sets of
curves become closer in the 600 to 650 nm interval, they remain relatively far apart in
650 to 700 nm interval. This can be explained by the relatively low absorption of light by
both MetHb and SHb in this interval (Fig. 2.2 (b)). Thus, an increase in blood content
will have a negligible impact on the reflectance values within this interval.
4.2 Cyanotic Appearance Changes
We remark that, as reported in the biomedical literature (e.g., [36, 38, 41, 44]), skin spectral
responses associated with methemoglobinemia and sulfhemoglobinemia lead to cyanotic
skin appearances. One can expect that these appearances may vary according with the
amounts of MetHb and SHb present in a subject’s blood stream. In addition, it seems
plausible that their characteristic chromatic attributes may be intensified as the blood
content of the examined skin site increases. However, a quantitative investigation of the
impact of these biophysical parameters on a subject’s cyanotic appearance has not been
performed to date.
In order to perform such an investigation, we employed the dysfunctional reflectance
curves obtained from our in silico experiments (Section 4.1) to generate skin swatches de-
picting the appearance changes associated with these curves. In total, four sets of swatches
were generated, one for each vrdblood value considered in our experiments, namely 2%, 5% 10%
and 15%. These sets are presented in Figs. 4.5 to 4.8, respectively, along with the CIELAB
∆E?ab differences computed for each pair of swatches generated for the same abnormal
amounts of MetHb and SHb.
As it can be observed in Fig. 4.5, an increase in the methemoglobinemia and sulfhe-
moglobinemia severity levels led to a pale appearance when we considered vrdblood equal to
2%. In addition, it also led to more distinguishable ∆E?ab differences between pairs of
swatches generated considering the same amounts of MetHb and SHb.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 4.1: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 2%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 15◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 4.2: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 5%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 15◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 4.3: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 10%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 15◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 4.4: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 15%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 15◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3.The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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10%
MetHb
20% 30% 40% 50% 60% 70% 80%
SHb
2.40∆E?ab 4.20 6.03 7.94 10.08 12.25 14.57 17.43
Figure 4.5: Skin swatches generated using the dysfunctional reflectance curves provided in
Fig. 4.1, which were obtained considering skin specimen characterized by a reticular blood con-
tent (vrdblood) equal to 2% and increasing amounts of methemoglobin (MetHb) and sulfhemoglobin
(SHb), from 10% to 80%. The bottom row presents the the CIELAB ∆E?ab differences for each
pair of MetHb and SHb swatches. The RGB values associated with each swatch depicted above
can be found in Table A.1 in Appendix A.
10%
MetHb
20% 30% 40% 50% 60% 70% 80%
SHb
2.31∆E?ab 3.72 5.13 6.51 8.39 10.28 12.76 15.75
Figure 4.6: Skin swatches generated using the dysfunctional reflectance curves provided in
Fig. 4.2, which were obtained considering skin specimen characterized by a reticular blood con-
tent (vrdblood) equal to 5% and increasing amounts of methemoglobin (MetHb) and sulfhemoglobin
(SHb), from 10% to 80%. The bottom row presents the the CIELAB ∆E?ab differences for each
pair of MetHb and SHb swatches. The RGB values associated with each swatch depicted above
can be found in Table A.2 in Appendix A.
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10%
MetHb
20% 30% 40% 50% 60% 70% 80%
SHb
2.23∆E?ab 2.93 3.51 4.21 4.91 5.62 6.90 8.88
Figure 4.7: Skin swatches generated using the dysfunctional reflectance curves provided in
Fig. 4.3, which were obtained considering skin specimen characterized by a reticular blood con-
tent (vrdblood) equal to 10% and increasing amounts of methemoglobin (MetHb) and sulfhemoglobin
(SHb), from 10% to 80%. The bottom row presents the the CIELAB ∆E?ab differences for each
pair of MetHb and SHb swatches. The RGB values associated with each swatch depicted above
can be found in Table A.3 in Appendix A.
10%
MetHb
20% 30% 40% 50% 60% 70% 80%
SHb
2.11∆E?ab 2.67 2.89 3.11 3.44 3.48 3.86 4.84
Figure 4.8: Skin swatches generated using the dysfunctional reflectance curves provided in
Fig. 4.4, which were obtained considering skin specimen characterized by a reticular blood con-
tent (vrdblood) equal to 15% and increasing amounts of methemoglobin (MetHb) and sulfhemoglobin
(SHb), from 10% to 80%. The bottom row presents the the CIELAB ∆E?ab differences for each
pair of MetHb and SHb swatches. The RGB values associated with each swatch depicted above
can be found in Table A.4 in Appendix A.
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As we employed higher values for vrdblood, the impact of increasing severity levels of
methemoglobinemia and sulfhemoglobinemia on the swatches’ appearance became more
pronounced, with more characteristic cyanotic hues being elicited under these conditions.
More specifically, one can observe a transition to red-purple (MetHb swatches) and grey
(SHb swatches) hues in the 5% case (Fig. 4.6), to purple (MetHb swatches) and blue (SHb
swatches) hues in the 10% case (Fig. 4.7), and to purple (MetHb swatches) and more
saturated blue (SHb swatches) hues in the 15% case (Fig. 4.8).
The visual inspection of the swatches presented in Figs. 4.5 to 4.8 and the verifica-
tion of their respective CIELAB ∆E?ab differences reveal another relevant trend that can
be summarized as follows. Although one can observe transitions to more characteristic
cyanotic hues as higher vrdblood values are employed, the distinguishable CIELAB ∆E
?
ab dif-
ferences between pairs of swatches generated considering the same amounts of MetHb and
SHb decreases. In practical terms, while a cyanotic appearance becomes more evident, the
differentiation of their cause being an abnormal amount of MetHb or SHb becomes more
problematic.
4.3 Proposed Detection and Differentiation Protocol
The observations reported in Section 4.2 indicate that the visual assessment of a patient’s
cyanotic appearance is not a reliable candidate for the differentiation of methemoglobinemia
and sulfhemoglobinemia. However, it can be used to assist the detection of these disorders.
More specifically, once a cyanotic appearance has been observed in a patient, other more
common cyanosis-eliciting conditions may be ruled out using diagnosis-aiding tools usually
available to the medical staff. For example, as mentioned earlier, cyanosis is normally
associated with the presence of high levels of deoxygenated hemoglobin in the dermal
tissues [17]. Thus, if a patient with a high level (above 90%) of oxygenated (saturated)
arterial hemoglobin develops a cyanotic appearance, it is likely that such an appearance is
being elicited by a dyshemoglobinemia disorder [39]. We remark that oxygen saturation
levels can be quickly measured using a pulse oximeter [31], a device commonly available at
the point of care of most medical settings.
After it has been detected that a patient is being subjected to either methemoglobinemia
or sulfhemoglobinemia, the medical staff is left with the task of determining which of these
conditions should be targeted for treatment. In order to accomplish this differentiation
task in a cost-effective manner, ideally one would like to resort to a noninvasive procedure.
Accordingly, we propose a procedure formulated using selected reflectance values obtained
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at the patient’s cyanotic fingertips. In the remainder of this chapter, we outline this
procedure and evaluate its effectiveness.
From fundamental calculus [51], we know that the curve representing a differentiable
function y = f(x) is concave up on the interval where y′ is increasing, and concave down on
a interval where y′ is decreasing. Moreover, assuming that y = f(x) is twice differentiable
on an interval I, then the curve representing f(x) over I is concave up if y′′ > 0, and
concave down if y′′ < 0.
In our investigation, f(x) corresponds to a modeled reflectance curve ρ(λ), where λ
represents the wavelength of interest. Upon a closer examination of the dysfunctional
reflectance curves (Section 4.1) obtained from our in silico experiments, one can observe a
markedly distinct behavior of the MetHb and SHb curves on the 605 to 635 nm interval.
More specifically, while the curves obtained considering abnormal amounts of MetHb are
concave down on this interval, the curves obtained considering abnormal amounts of SHb
are concave up. These observations suggested that the sign of the second derivative of
ρ(λ) at the center (620 nm) of this interval can be used to differentiate reflectance curves
resulting from the presence of abnormal amounts of MetHb and SHb in blood-perfused
cutaneous tissues, with a ’-’ sign indicating the former and a ’+’ sign indicating the latter.
We note that the second derivative of a dysfunctional reflectance curve at 620 nm can
be numerically computed using the following three point central difference formula [37]:
y′′(620) =
ρ(605)− 2 ρ(620) + ρ(635)
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, (4.1)
where ρ(605), ρ(620) and ρ(635) correspond to reflectance values at 605, 620 and 635 nm,
respectively.
Since, for differentiation purposes, we are only interested in the sign of the second
derivative, the denominator in Equation 4.1 can be omitted. Accordingly, we employed the
following simplified formula to obtain the sign of the second derivative of the dysfunctional
reflectance curves at 620 nm:
y′′(620) = ρ(605)− 2 ρ(620) + ρ(635). (4.2)
Using Equation 4.2 and ρ(605), ρ(620) and ρ(635) values extracted from the dysfunc-
tional reflectance curves presented in Section 4.1, we computed the signs of their respective
second derivative at 620 nm. We remark that these curves were computed considering an
angle of incidence equal to 15◦. It is appropriate, however, to account for possible changes
in the measurement conditions that can take place when one employs an actual optical
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device to collect reflectance data. For example, one can expect angular variations with
respect to the angle of incidence due to slight curvature of the palmar fingertip. For this
reason, we also repeated our in silico experiments considering angles of incidences equal
to 0◦, 30◦ and 45◦, and extracted the ρ(605), ρ(620) and ρ(635) values from the resulting
dysfunctional reflectance curves (provided in Appendix B). We then used Equation 4.2 and
these reflectance values to compute the signs of the second derivatives of these curves at
620 nm. As it can be observed in the aggregated outcomes of these sign computations
presented in Tables 4.1 to 4.4, we were able to differentiate between methemoglobinemia
and sulfhemoglobinemia in all tested instances.
MetHb SHb
0◦ 15◦ 30◦ 45◦ 0◦ 15◦ 30◦ 45◦
10% – – – – + + + +
20% – – – – + + + +
30% – – – – + + + +
40% – – – – + + + +
50% – – – – + + + +
60% – – – – + + + +
70% – – – – + + + +
80% – – – – + + + +
Table 4.1: Second derivative signs (at 620 nm) of the dysfunctional reflectance curves resulting
from our in silico experiments considering vrdblood equal to 2%. The signs were obtained using
Equation 4.2 and the reflectance values extracted from these curves. These values are provided
in Tables C.1 to C.4 (Appendix C). The curves were computed using the Hylios model [65], the
specimen’s characterization parameter values presented in Table 3.1 and considering four angles
of incidence (0◦, 15◦, 30◦ and 45◦) as well as distinct severity levels of methemoglobinemia and
sulfhemoglobinemia (10% to 80%). The concentrations of dysfunctional (MetHb and SHb) and
functional hemoglobins associated with these levels are provided in Tables 3.2 and 3.3.
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MetHb SHb
0◦ 15◦ 30◦ 45◦ 0◦ 15◦ 30◦ 45◦
10% – – – – + + + +
20% – – – – + + + +
30% – – – – + + + +
40% – – – – + + + +
50% – – – – + + + +
60% – – – – + + + +
70% – – – – + + + +
80% – – – – + + + +
Table 4.2: Second derivative signs (at 620 nm) of the dysfunctional reflectance curves resulting
from our in silico experiments considering vrdblood equal to 5%. The signs were obtained using
Equation 4.2 and the reflectance values extracted from these curves. These values are provided
in Tables C.5 to C.8 (Appendix C). The curves were computed using the Hylios model [65], the
specimen’s characterization parameter values presented in Table 3.1 and considering four angles
of incidence (0◦, 15◦, 30◦ and 45◦) as well as distinct severity levels of methemoglobinemia and
sulfhemoglobinemia (10% to 80%). The concentrations of dysfunctional (MetHb and SHb) and
functional hemoglobins associated with these levels are provided in Tables 3.2 and 3.3.
MetHb SHb
0◦ 15◦ 30◦ 45◦ 0◦ 15◦ 30◦ 45◦
10% – – – – + + + +
20% – – – – + + + +
30% – – – – + + + +
40% – – – – + + + +
50% – – – – + + + +
60% – – – – + + + +
70% – – – – + + + +
80% – – – – + + + +
Table 4.3: Second derivative signs (at 620 nm) of the dysfunctional reflectance curves resulting
from our in silico experiments considering vrdblood equal to 10%. The signs were obtained using
Equation 4.2 and the reflectance values extracted from these curves. These values are provided
in Tables C.9 to C.12 (Appendix C). The curves were computed using the Hylios model [65], the
specimen’s characterization parameter values presented in Table 3.1 and considering four angles
of incidence (0◦, 15◦, 30◦ and 45◦) as well as distinct severity levels of methemoglobinemia and
sulfhemoglobinemia (10% to 80%). The concentrations of dysfunctional (MetHb and SHb) and
functional hemoglobins associated with these levels are provided in Tables 3.2 and 3.3.
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MetHb SHb
0◦ 15◦ 30◦ 45◦ 0◦ 15◦ 30◦ 45◦
10% – – – – + + + +
20% – – – – + + + +
30% – – – – + + + +
40% – – – – + + + +
50% – – – – + + + +
60% – – – – + + + +
70% – – – – + + + +
80% – – – – + + + +
Table 4.4: Second derivative signs (at 620 nm) of the dysfunctional reflectance curves resulting
from our in silico experiments considering vrdblood equal to 15%. The signs were obtained using
Equation 4.2 and the reflectance values extracted from these curves. These values are provided
in Tables C.13 to C.16 (Appendix C). The curves were computed using the Hylios model [65], the
specimen’s characterization parameter values presented in Table 3.1 and considering four angles
of incidence (0◦, 15◦, 30◦ and 45◦) as well as distinct severity levels of methemoglobinemia and
sulfhemoglobinemia (10% to 80%). The concentrations of dysfunctional (MetHb and SHb) and
functional hemoglobins associated with these levels are provided in Tables 3.2 and 3.3.
It is worth noting that reflectance values measured using actual devices, such as spec-
trophotometers, may be subjected to uncertainties associated with the device. A high
precision device will have an uncertainty of ±0.001 or 0.1% [52]. A low precision device
may have an uncertainty close to 1% [52, 106]. In order to assess the consistency of our ob-
servations with respect to these random fluctuations, we also performed a set of simulations
considering the presence of random noise (±1%) in our simulations. Again, we were able to
differentiate between methemoglobinemia and sulfhemoglobinemia in all tested instances.
All reflectance datasets associated with these instances are provided in Appendix C.
For conciseness, we selected to present in the remainder of this section the reflectance
values used to obtain the signs associated with the most difficult differentiation instances
found in our experiments. These instances, in which one can observe the closest proximity
between MetHb and SHb in the selected spectral interval, correspond to the case where we
set vrdblood equal to 15%. The ρ(605), ρ(620) and ρ(635) values extracted from the curves
associated with these test instances are presented in Table 4.5, and the corresponding
second derivative signed values (to enable the quantitative verification of the correctness
of our calculations) computed using Equation 4.2 are provided in Table 4.6.
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MetHb SHb
605 620 635 605 620 635
10% 0.2320 0.2890 0.3141 0.2246 0.2578 0.3160
20% 0.2047 0.2330 0.2419 0.1940 0.1986 0.2427
30% 0.1828 0.1964 0.1973 0.1723 0.1634 0.2038
40% 0.1681 0.1707 0.1693 0.1574 0.1440 0.1724
50% 0.1566 0.1533 0.1477 0.1455 0.1308 0.1530
60% 0.1457 0.1415 0.1328 0.1378 0.1210 0.1393
70% 0.1374 0.1337 0.1248 0.1322 0.1150 0.1278
80% 0.1310 0.1256 0.1172 0.1263 0.1108 0.1208
Table 4.5: Reflectance values at 605, 620 and 635 nm extracted from dysfunctional curves com-
puted using the HyLIoS model [25], the specimen’s characterization parameter values presented
in Table 3.1 and accounting for the presence of random noise (±1%) in our simulations. In the
computation of these curves, we considered an angle of incidence of 15◦, a reticular blood content
(vrdblood) equal to 15% and distinct severity levels of methemoglobinemia and sulfhemoglobinemia
(10% to 80%). The concentrations of dysfunctional (MetHb and SHb) and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3.
10% 20% 30% 40% 50% 60% 70% 80%
MetHb -0.0319 -0.0194 -0.0127 -0.0040 -0.0023 -0.0045 -0.0052 -0.0030
SHb +0.0250 +0.0395 +0.0493 +0.0418 +0.0369 +0.0351 +0.0300 +0.0255
Table 4.6: Second derivative values computed using the reflectance values provided in Table 4.5
and Equation 4.2 for distinct severity levels of methemoglobinemia and sulfhemoglobinemia (10%
to 80%). The concentrations of dysfunctional (MetHb and SHb) and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3.
Previously, Baranoski et al. [12] have also proposed five-point and three-point central
difference formulas for differentiating between methemoglobinemia and sulfhemoglobine-
mia. In their work, they were able to differentiate these disorders within a severity level
range between 20% and 70% and considering the reticular blood content equal to 5%. Us-
ing the proposed formula, we were able to differentiate these disorders within a broader
severity level range (from 10% to 80%) and considering observed [21] physiological varia-
tions in the reticular blood content (from 2% to 15%). These observations indicate that
the proposed three-point formula enables a wider range of sensitivity in the differentiation
of methemoglobinemia and sulfhemoglobinemia without incurring into additional compu-
tational costs.
In summary, based on our in silico experimental findings, we propose a protocol in which
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a subject’s cyanotic appearance is employed to assist the detection of methemoglobinemia
and sulfhemoglobinemia, and an optical procedure is used to differentiate these disorders.
This procedure, in turn, would consist in the noninvasive measurement of three reflectance
values at the patient’s cyanotic fingertips followed by the sign computation using Equa-
tion 4.2. We note that the proposed differentiation procedure would require only three
measurements, which could be obtained in situ (without the need, for example, of sending
blood samples for analysis elsewhere) using a hand-held spectrophotometer, a relatively
inexpensive device in comparison with co-oximeters and blood gas analysers. Moreover,
these measurements would be performed at wavelengths within the visible (harmless) re-
gion of the light spectrum. These aspects would likely make it attractive for use at the
point of care of low-resources medical settings.
Since other noninvasive optical monitoring procedures, such as pulse oximetry [31], also
rely on light and skin interactions in the near-infrared domain, one might question the rea-
son why we have not extended our investigation to this spectral domain. Although our
in silico experimental framework can be used to obtain skin reflectance readings from the
ultraviolet to the infrared domain, our investigation was centered at the visible domain
for the following reasons. First, one of the focal points of our investigation, cyanosis, is
directly associated with skin spectral responses in this spectral domain. Second, there is a
relative scarcity of reliable data with respect to the extinction coefficients of MetHb and
SHb outside the visible domain. The available data (e.g., [82, 103]) indicates that the
extinction coefficients of MetHb and SHb in the near-infrared domain may be one order of
magnitude lower than their visible domain counterparts. This, in turn, suggests that the
chances of finding significant spectral features to allow a reliable differentiation of methe-
moglobinemia and sulfhemoglobinemia are small in the near-infrared domain. Nonetheless,
as reliable near-infrared extinction coefficient data for MetHb and SHb become available,
it will be worthwhile to investigate the possibility of finding differentiation features for
methemoglobinemia and sulfhemoglobinemia in this spectral domain as well.
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Chapter 5
Conclusion and Future Prospects
In this work, we have quantitatively examined the connection between the onset of cyanosis
and distinct severity levels of methemoglobinemia and sulfhemoglobinemia. More specifi-
cally, we have demonstrated the impact of different amounts of MetHb and SHb on cyanotic
chromatic attributes of a specimen also subjected to variations on dermal blood content.
We have also assessed the impact of these biophysical parameters on the specimen’s spectral
responses. Building on the findings derived from our in silico findings, we have proposed
a cost-effective protocol for the detection and differentiation of methemoglobinemia and
sulfhemoglobinemia. Our in silico evaluation of its effectiveness and sensitivity range sug-
gests that it can represent a promising alternative to the technologies currently used in the
detection and differentiation of these dyshemoglobinemia disorders.
It has been long recognized [93, 95] that in silico experiments performed through pre-
dictive computer simulations can be successfully employed to predict the quantitative be-
haviour of complex biological systems, to accelerate the hypothesis generation and valida-
tion cycles of biomedical research, notably those that cannot be performed using traditional
“wet” laboratory technologies, and to drive new scientific investigations. It is important
to keep in mind, however, that a computer simulation has a limited value if it is not
being supported and verified against reliable data obtained through actual experiments
performed under in vivo and/or in vitro conditions. Furthermore, the pairing of computer
simulations with actual experiments can contribute to a more straightforward translation
of research outcomes obtained in silico to clinical practice. These experiments, for exam-
ple, could consist in reflectance measurements performed (in vivo) on a patient subjected
to a dyshemoglobinemia disease, followed by a collection of a blood sample to determine
(in vitro) the MetHb and SHb levels in his/her blood stream.
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Viewed in this context, our in silico findings and, in particular, the verification of the
proposed protocol’s effectiveness would certainly benefit from confirmation through in vivo
and/or in vitro experiments. We note, however, that the scarcity of in vivo and in vitro
experiments involving the measurement of chromatic and spectral data associated with
the onset of methemoglobinemia and sulfhemoglobinemia has motivated our use of an in
silico approach in the first place. Moreover, we remark that our in silico experiments were
performed using a first-principles model of light and skin interactions, whose predictive
capabilities have been extensively evaluated in previous works [13, 17, 18, 25, 90]. Also,
to the best of our knowledge, we have employed the most reliable supporting biophysical
data, such as the spectral extinction coefficients for methemoglobin [77] and sulfhemoglobin
[103], provided in the biomedical literature. Hence, we are confident that our findings can
be corroborated by in vivo and/or in vitro measured data as it becomes available.
As outlined above, the investigation presented in this thesis also highlighted the need for
databases depicting measured chromatic and spectral data obtained from skin specimens
subject to pathological conditions, particularly those affecting the patients’ appearance
and posing a high risk of morbidity and mortality for them. In order to improve this
situation, we believe that the biomedical community should support efforts directed to the
creation of such databases. These should include, but not be limited to data related to
dyshemoglobinemia disorders. These efforts would likely involve the establishment of syn-
ergistic cooperations between researchers and medical institutions involved in the diagnosis
and treatment of the targeted pathological conditions. Once the databases are created, it
would be essential that they are made publicly accessible so that they can be fully verified
and employed by the entire biomedical community.
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Appendix A
RGB Data
In this appendix, we provide the RGB values computed for the swatches presented in
Chapter 4.
Table A.1: RGB values computed for the swatches depicted in Fig. 4.5.
MetHb SHb
R G B R G B
10% 247 165 152 244 167 152
20% 240 165 152 236 170 154
30% 235 166 152 229 174 155
40% 230 167 153 224 178 157
50% 227 169 153 219 183 159
60% 224 170 153 216 188 161
70% 222 172 154 213 193 163
80% 220 173 155 211 200 166
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Table A.2: RGB values computed for the swatches depicted in Fig. 4.6.
MetHb SHb
R G B R G B
10% 219 140 146 215 141 146
20% 209 140 146 204 143 147
30% 202 141 147 195 146 148
40% 195 142 147 188 149 149
50% 190 142 147 181 152 150
60% 185 143 147 176 156 151
70% 182 144 148 173 161 152
80% 179 146 148 170 168 154
Table A.3: RGB values computed for the swatches depicted in Fig. 4.7.
MetHb SHb
R G B R G B
10% 194 133 145 190 133 146
20% 181 133 146 176 135 146
30% 172 134 146 165 136 147
40% 165 134 147 157 137 147
50% 159 134 147 151 138 148
60% 154 135 147 146 140 149
70% 150 135 148 142 143 149
80% 146 136 148 140 147 150
Table A.4: RGB values computed for the swatches depicted in Fig. 4.8.
MetHb SHb
R G B R G B
10% 178 132 146 173 133 146
20% 164 133 146 159 133 146
30% 155 133 146 149 134 147
40% 148 134 147 141 135 147
50% 142 134 147 135 135 148
60% 137 134 147 131 136 148
70% 134 134 148 128 137 149
80% 131 134 148 126 139 149
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Appendix B
Additional Dysfunctional Reflectance
Curves
In this appendix, we provide the dysfunctional reflectance curves resulting from repeating
our in silico experiments (described in Sections 3.1, 3.2 and 4.1) for distinct angles of
incidence, namely 0◦ (Figs. B.1 to B.4), 30◦ (Figs. B.5 to B.8) and 45◦ (Figs. B.9 to
B.12).
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.1: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 2%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 0◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.2: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 5%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 0◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.3: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 10%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 0◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.4: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 15%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 0◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
53
(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.5: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 2%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 30◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.6: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 5%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 30◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
55
(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.7: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 10%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 30◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.8: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 15%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 30◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.9: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 2%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 45◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.10: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 5%. These curves were obtained using the HyLIoS [25] model and
considering an angle of incidence equal to 45◦. Each graph corresponds to a distinct severity level
of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%, (e) 50%,
(f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional hemoglobins
associated with these levels are provided in Tables 3.2 and 3.3. The remaining parameters values
used in the specimen’s characterization are provided in Table 3.1.
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.11: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 10%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 45◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
60
(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure B.12: Graphs depicting reflectance curves resulting from increasing amounts of methe-
moglobin (MetHb) and sulfhemoglobin (SHb) in a skin specimen characterized by a reticular
blood content (vrdblood) equal to 15%. These curves were obtained using the HyLIoS [25] model
and considering an angle of incidence equal to 45◦. Each graph corresponds to a distinct sever-
ity level of methemoglobinemia and sulfhemoglobinemia: (a) 10%, (b) 20%, (c) 30%, (d) 40%,
(e) 50%, (f) 60%, (g) 70% and (h) 80%. The concentrations of dysfunctional and functional
hemoglobins associated with these levels are provided in Tables 3.2 and 3.3. The remaining
parameters values used in the specimen’s characterization are provided in Table 3.1.
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Appendix C
Reflectance Data
In this appendix, we provide the reflectance values used to compute the signs depicted in
Tables 4.1 to 4.4 in (Chapter 4) considering different values for the blood content of the
reticular dermis (vrdblood) and distinct angles of incidence.
Table C.1: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 2% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.5360 0.5921 0.6220 0.5270 0.5638 0.6194
20% 0.5046 0.5410 0.5574 0.4909 0.5042 0.5608
30% 0.4781 0.5017 0.5093 0.4606 0.4572 0.5163
40% 0.4529 0.4693 0.4724 0.4361 0.4200 0.4798
50% 0.4321 0.4406 0.4391 0.4137 0.3899 0.4491
60% 0.4132 0.4165 0.4122 0.3938 0.3652 0.4231
70% 0.3963 0.3943 0.3896 0.3771 0.3432 0.3993
80% 0.3817 0.3757 0.3682 0.3620 0.3245 0.3786
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Table C.2: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 2% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.5327 0.5888 0.6183 0.5235 0.5595 0.6163
20% 0.4998 0.5378 0.5551 0.4882 0.4997 0.5574
30% 0.4737 0.4980 0.5057 0.4584 0.4532 0.5119
40% 0.4492 0.4645 0.4672 0.4327 0.4180 0.4758
50% 0.4289 0.4378 0.4362 0.4111 0.3881 0.4454
60% 0.4107 0.4136 0.4087 0.3920 0.3624 0.4200
70% 0.3939 0.3928 0.3862 0.3744 0.3411 0.3967
80% 0.3782 0.3727 0.3660 0.3591 0.3215 0.3765
Table C.3: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 2% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.5239 0.5810 0.6095 0.5153 0.5522 0.6084
20% 0.4934 0.5300 0.5457 0.4789 0.4898 0.5486
30% 0.4642 0.4898 0.4976 0.4500 0.4458 0.5035
40% 0.4421 0.4562 0.4595 0.4263 0.4110 0.4663
50% 0.4207 0.4289 0.4282 0.4045 0.3806 0.4360
60% 0.4028 0.4059 0.4003 0.3852 0.3553 0.4100
70% 0.3863 0.3847 0.3786 0.3674 0.3332 0.3885
80% 0.3710 0.3666 0.3581 0.3525 0.3152 0.3681
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Table C.4: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 2% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.5176 0.5742 0.6025 0.5090 0.5451 0.6023
20% 0.4877 0.5232 0.5381 0.4743 0.4852 0.5412
30% 0.4594 0.4829 0.4900 0.4462 0.4410 0.4969
40% 0.4370 0.4509 0.4523 0.4209 0.4048 0.4616
50% 0.4171 0.4234 0.4218 0.3996 0.3759 0.4304
60% 0.3981 0.4000 0.3950 0.3799 0.3518 0.4060
70% 0.3821 0.3802 0.3732 0.3634 0.3307 0.3830
80% 0.3674 0.3622 0.3536 0.3496 0.3122 0.3646
Table C.5: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 5% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.4020 0.4646 0.4963 0.3916 0.4308 0.4946
20% 0.3665 0.4045 0.4189 0.3535 0.3624 0.4233
30% 0.3372 0.3600 0.3643 0.3222 0.3141 0.3718
40% 0.3137 0.3255 0.3252 0.2964 0.2778 0.3329
50% 0.2924 0.2974 0.2938 0.2757 0.2507 0.3019
60% 0.2744 0.2746 0.2670 0.2579 0.2288 0.2761
70% 0.2596 0.2550 0.2458 0.2418 0.2095 0.2555
80% 0.2459 0.2376 0.2276 0.2285 0.1940 0.2368
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Table C.6: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 5% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.3991 0.4617 0.4937 0.3884 0.4267 0.4917
20% 0.3645 0.4015 0.4161 0.3503 0.3594 0.4203
30% 0.3341 0.3573 0.3619 0.3184 0.3117 0.3694
40% 0.3103 0.3229 0.3223 0.2947 0.2765 0.3306
50% 0.2903 0.2941 0.2903 0.2730 0.2479 0.2987
60% 0.2715 0.2733 0.2646 0.2557 0.2265 0.2743
70% 0.2573 0.2529 0.2435 0.2400 0.2081 0.2535
80% 0.2445 0.2360 0.2253 0.2265 0.1932 0.2351
Table C.7: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 5% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.3918 0.4538 0.4838 0.3811 0.4191 0.4818
20% 0.3570 0.3932 0.4077 0.3437 0.3520 0.4116
30% 0.3293 0.3506 0.3553 0.3137 0.3051 0.3609
40% 0.3057 0.3167 0.3157 0.2897 0.2706 0.3231
50% 0.2847 0.2904 0.2845 0.2683 0.2438 0.2938
60% 0.2669 0.2673 0.2594 0.2510 0.2222 0.2686
70% 0.2531 0.2470 0.2388 0.2358 0.2053 0.2483
80% 0.2392 0.2320 0.2224 0.2235 0.1908 0.2299
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Table C.8: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 5% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.3866 0.4475 0.4777 0.3781 0.4144 0.4749
20% 0.3534 0.3891 0.4026 0.3412 0.3485 0.4063
30% 0.3266 0.3467 0.3508 0.3113 0.3038 0.3583
40% 0.3045 0.3145 0.3126 0.2875 0.2706 0.3208
50% 0.2842 0.2870 0.2823 0.2679 0.2451 0.2908
60% 0.2680 0.2655 0.2593 0.2525 0.2244 0.2679
70% 0.2533 0.2482 0.2402 0.2384 0.2072 0.2483
80% 0.2411 0.2332 0.2232 0.2253 0.1945 0.2320
Table C.9: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis (vrdblood) equal to 10% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.2937 0.3549 0.3843 0.2846 0.3204 0.3831
20% 0.2603 0.2948 0.3058 0.2492 0.2551 0.3103
30% 0.2345 0.2524 0.2554 0.2223 0.2125 0.2615
40% 0.2152 0.2227 0.2190 0.2012 0.1845 0.2262
50% 0.1974 0.1992 0.1930 0.1848 0.1638 0.2003
60% 0.1841 0.1810 0.1731 0.1716 0.1495 0.1803
70% 0.1729 0.1670 0.1578 0.1602 0.1380 0.1653
80% 0.1636 0.1559 0.1461 0.1516 0.1300 0.1525
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Table C.10: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 10% and the angle of incidence equal to
15°.
MetHb SHb
605 620 635 605 620 635
10% 0.2916 0.3522 0.3812 0.2816 0.3172 0.3798
20% 0.2588 0.2915 0.3036 0.2468 0.2514 0.3070
30% 0.2340 0.2509 0.2525 0.2210 0.2115 0.2584
40% 0.2125 0.2210 0.2185 0.1994 0.1838 0.2249
50% 0.1970 0.1975 0.1923 0.1834 0.1632 0.1989
60% 0.1836 0.1799 0.1723 0.1706 0.1489 0.1795
70% 0.1716 0.1667 0.1573 0.1599 0.1380 0.1643
80% 0.1623 0.1548 0.1458 0.1513 0.1294 0.1522
Table C.11: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 10% and the angle of incidence equal to
30°.
MetHb SHb
605 620 635 605 620 635
10% 0.2854 0.3440 0.3736 0.2769 0.3113 0.3718
20% 0.2543 0.2867 0.2971 0.2425 0.2476 0.3003
30% 0.2301 0.2467 0.2481 0.2167 0.2094 0.2539
40% 0.2107 0.2165 0.2150 0.1979 0.1807 0.2202
50% 0.1935 0.1955 0.1887 0.1823 0.1628 0.1962
60% 0.1811 0.1785 0.1707 0.1695 0.1484 0.1772
70% 0.1710 0.1640 0.1561 0.1598 0.1382 0.1627
80% 0.1623 0.1544 0.1449 0.1514 0.1310 0.1509
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Table C.12: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 10% and the angle of incidence equal to
45°.
MetHb SHb
605 620 635 605 620 635
10% 0.2854 0.3408 0.3696 0.2762 0.3085 0.3678
20% 0.2558 0.2852 0.2953 0.2439 0.2494 0.2977
30% 0.2317 0.2465 0.2480 0.2205 0.2114 0.2533
40% 0.2142 0.2188 0.2160 0.2008 0.1862 0.2225
50% 0.1982 0.1985 0.1936 0.1874 0.1683 0.1989
60% 0.1878 0.1832 0.1752 0.1761 0.1559 0.1820
70% 0.1772 0.1707 0.1624 0.1671 0.1464 0.1681
80% 0.1681 0.1616 0.1526 0.1590 0.1396 0.1581
Table C.13: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 15% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.2359 0.2894 0.3190 0.2265 0.2580 0.3164
20% 0.2068 0.2345 0.2428 0.1964 0.1990 0.2461
30% 0.1847 0.1979 0.1977 0.1751 0.1658 0.2039
40% 0.1689 0.1727 0.1688 0.1585 0.1440 0.1744
50% 0.1562 0.1550 0.1490 0.1464 0.1306 0.1538
60% 0.1460 0.1420 0.1350 0.1377 0.1216 0.1403
70% 0.1380 0.1327 0.1249 0.1310 0.1157 0.1287
80% 0.1321 0.1250 0.1177 0.1251 0.1109 0.1215
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Table C.14: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 15% and the angle of incidence equal to
15°.
MetHb SHb
605 620 635 605 620 635
10% 0.2336 0.2883 0.3161 0.2250 0.2560 0.3131
20% 0.2055 0.2321 0.2406 0.1948 0.1975 0.2444
30% 0.1838 0.1965 0.1963 0.1734 0.1646 0.2020
40% 0.1682 0.1719 0.1677 0.1575 0.1436 0.1737
50% 0.1550 0.1545 0.1482 0.1459 0.1300 0.1537
60% 0.1459 0.1413 0.1336 0.1374 0.1219 0.1384
70% 0.1382 0.1325 0.1245 0.1313 0.1156 0.1290
80% 0.1317 0.1257 0.1177 0.1255 0.1117 0.1209
Table C.15: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 15% and the angle of incidence equal to
30°.
MetHb SHb
605 620 635 605 620 635
10% 0.2307 0.2823 0.3096 0.2220 0.2507 0.3071
20% 0.2023 0.2280 0.2364 0.1927 0.1949 0.2401
30% 0.1816 0.1946 0.1933 0.1721 0.1643 0.1992
40% 0.1670 0.1698 0.1668 0.1573 0.1441 0.1713
50% 0.1556 0.1536 0.1484 0.1463 0.1311 0.1514
60% 0.1461 0.1410 0.1351 0.1384 0.1230 0.1390
70% 0.1391 0.1328 0.1258 0.1318 0.1176 0.1301
80% 0.1333 0.1264 0.1192 0.1275 0.1142 0.1226
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Table C.16: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis (vrdblood) equal to 15% and the angle of incidence equal to
45°.
MetHb SHb
605 620 635 605 620 635
10% 0.2328 0.2819 0.3062 0.2248 0.2516 0.3040
20% 0.2061 0.2303 0.2367 0.1970 0.1987 0.2405
30% 0.1872 0.1985 0.1973 0.1789 0.1693 0.2020
40% 0.1742 0.1759 0.1712 0.1653 0.1512 0.1762
50% 0.1626 0.1610 0.1548 0.1549 0.1403 0.1595
60% 0.1549 0.1500 0.1427 0.1467 0.1335 0.1472
70% 0.1480 0.1418 0.1347 0.1416 0.1279 0.1376
80% 0.1428 0.1371 0.1286 0.1380 0.1251 0.1318
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Appendix D
Reflectance Data Subjected to
Random Fluctuations
In this appendix, we provide the reflectance values accounting for the ±1% random noise
in our simulations.
Table D.1: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 2% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.5353 0.5946 0.6203 0.5309 0.5588 0.6256
20% 0.5045 0.5424 0.5523 0.4937 0.5011 0.5626
30% 0.4763 0.5015 0.5124 0.4625 0.4614 0.5132
40% 0.4533 0.4709 0.4734 0.4343 0.4201 0.4801
50% 0.4333 0.4423 0.4400 0.4170 0.3861 0.4518
60% 0.4162 0.4131 0.4128 0.3976 0.3643 0.4258
70% 0.3925 0.3905 0.3857 0.3774 0.3426 0.4025
80% 0.3808 0.3773 0.3656 0.3615 0.3237 0.3780
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Table D.2: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 2% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.5327 0.5888 0.6183 0.5235 0.5595 0.6163
20% 0.4998 0.5378 0.5551 0.4882 0.4997 0.5574
30% 0.4737 0.4980 0.5057 0.4584 0.4532 0.5119
40% 0.4492 0.4645 0.4672 0.4327 0.4180 0.4758
50% 0.4289 0.4378 0.4362 0.4111 0.3881 0.4454
60% 0.4107 0.4136 0.4087 0.3920 0.3624 0.4200
70% 0.3939 0.3928 0.3862 0.3744 0.3411 0.3967
80% 0.3782 0.3727 0.3660 0.3591 0.3215 0.3765
Table D.3: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 2% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.5196 0.5847 0.6147 0.5117 0.5514 0.6068
20% 0.4942 0.5315 0.5449 0.4819 0.4931 0.5521
30% 0.4634 0.4865 0.4967 0.4535 0.4487 0.4988
40% 0.4419 0.4605 0.4581 0.4284 0.4138 0.4657
50% 0.4176 0.4291 0.4273 0.4015 0.3815 0.4368
60% 0.4006 0.4089 0.4034 0.3863 0.3584 0.4087
70% 0.3849 0.3867 0.3779 0.3689 0.3299 0.3911
80% 0.3699 0.3699 0.3587 0.3545 0.3181 0.3664
72
Table D.4: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 2% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.5183 0.5735 0.6046 0.5060 0.5481 0.6070
20% 0.4877 0.5230 0.5336 0.4709 0.4855 0.5436
30% 0.4569 0.4840 0.4947 0.4443 0.4432 0.4928
40% 0.4407 0.4522 0.4540 0.4234 0.4036 0.4623
50% 0.4199 0.4269 0.4218 0.4012 0.3764 0.4276
60% 0.3970 0.3990 0.3985 0.3827 0.3508 0.4079
70% 0.3837 0.3776 0.3752 0.3671 0.3318 0.3846
80% 0.3653 0.3620 0.3570 0.3507 0.3106 0.3637
Table D.5: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 5% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.3990 0.4644 0.4957 0.3944 0.4338 0.4941
20% 0.3662 0.4041 0.4165 0.3544 0.3650 0.4267
30% 0.3340 0.3607 0.3666 0.3198 0.3150 0.3692
40% 0.3166 0.3244 0.3269 0.2948 0.2752 0.3322
50% 0.2904 0.2955 0.2922 0.2756 0.2512 0.2993
60% 0.2771 0.2768 0.2694 0.2592 0.2298 0.2745
70% 0.2585 0.2557 0.2437 0.2399 0.2080 0.2573
80% 0.2453 0.2389 0.2296 0.2284 0.1936 0.2380
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Table D.6: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 5% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.3981 0.4648 0.4940 0.3863 0.4274 0.4885
20% 0.3615 0.4049 0.4119 0.3532 0.3628 0.4204
30% 0.3326 0.3570 0.3609 0.3200 0.3093 0.3700
40% 0.3092 0.3256 0.3203 0.2927 0.2792 0.3309
50% 0.2888 0.2919 0.2898 0.2706 0.2470 0.2996
60% 0.2729 0.2748 0.2672 0.2541 0.2271 0.2755
70% 0.2574 0.2544 0.2458 0.2394 0.2060 0.2547
80% 0.2432 0.2341 0.2236 0.2253 0.1917 0.2359
Table D.7: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 5% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.3936 0.4568 0.4850 0.3833 0.4200 0.4774
20% 0.3588 0.3912 0.4063 0.3472 0.3522 0.4099
30% 0.3320 0.3504 0.3577 0.3138 0.3052 0.3643
40% 0.3066 0.3194 0.3188 0.2914 0.2695 0.3254
50% 0.2855 0.2876 0.2824 0.2707 0.2446 0.2925
60% 0.2649 0.2651 0.2575 0.2513 0.2223 0.2662
70% 0.2551 0.2473 0.2394 0.2378 0.2055 0.2480
80% 0.2375 0.2334 0.2221 0.2233 0.1915 0.2318
74
Table D.8: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 5% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.3842 0.4519 0.4807 0.3816 0.4132 0.4745
20% 0.3539 0.3917 0.4041 0.3442 0.3499 0.4088
30% 0.3273 0.3497 0.3539 0.3133 0.3045 0.3608
40% 0.3020 0.3165 0.3131 0.2892 0.2699 0.3226
50% 0.2833 0.2854 0.2840 0.2654 0.2432 0.2924
60% 0.2681 0.2649 0.2602 0.2509 0.2225 0.2683
70% 0.2516 0.2499 0.2425 0.2375 0.2092 0.2459
80% 0.2422 0.2332 0.2233 0.2250 0.1929 0.2310
Table D.9: Reflectance values extracted from dysfunctional curves obtained considering the blood
content of the reticular dermis equal to 10% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.2936 0.3576 0.3877 0.2819 0.3196 0.3834
20% 0.2614 0.2924 0.3078 0.2468 0.2560 0.3076
30% 0.2350 0.2526 0.2570 0.2207 0.2130 0.2595
40% 0.2138 0.2245 0.2204 0.2022 0.1860 0.2252
50% 0.1967 0.2010 0.1943 0.1842 0.1631 0.2016
60% 0.1841 0.1806 0.1746 0.1731 0.1495 0.1795
70% 0.1745 0.1672 0.1587 0.1610 0.1381 0.1638
80% 0.1621 0.1574 0.1465 0.1512 0.1304 0.1525
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Table D.10: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 10% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.2910 0.3534 0.3798 0.2795 0.3181 0.3807
20% 0.2595 0.2935 0.3006 0.2490 0.2519 0.3090
30% 0.2347 0.2494 0.2528 0.2195 0.2103 0.2580
40% 0.2113 0.2219 0.2187 0.1994 0.1838 0.2234
50% 0.1977 0.1988 0.1909 0.1828 0.1645 0.1996
60% 0.1831 0.1804 0.1735 0.1711 0.1474 0.1780
70% 0.1719 0.1664 0.1559 0.1583 0.1385 0.1632
80% 0.1622 0.1552 0.1449 0.1519 0.1294 0.1518
Table D.11: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 10% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.2830 0.3429 0.3718 0.2745 0.3122 0.3753
20% 0.2529 0.2873 0.2991 0.2408 0.2484 0.3003
30% 0.2293 0.2472 0.2484 0.2165 0.2103 0.2558
40% 0.2104 0.2185 0.2139 0.1968 0.1793 0.2186
50% 0.1946 0.1974 0.1877 0.1839 0.1612 0.1947
60% 0.1825 0.1783 0.1697 0.1700 0.1482 0.1758
70% 0.1694 0.1655 0.1571 0.1588 0.1378 0.1615
80% 0.1632 0.1554 0.1438 0.1518 0.1311 0.1494
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Table D.12: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 10% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.2846 0.3403 0.3732 0.2771 0.3064 0.3679
20% 0.2563 0.2825 0.2930 0.2454 0.2519 0.2976
30% 0.2295 0.2444 0.2486 0.2204 0.2132 0.2525
40% 0.2142 0.2180 0.2148 0.2011 0.1878 0.2209
50% 0.1963 0.1986 0.1939 0.1856 0.1688 0.1981
60% 0.1890 0.1832 0.1753 0.1764 0.1554 0.1809
70% 0.1767 0.1714 0.1621 0.1666 0.1459 0.1686
80% 0.1695 0.1620 0.1538 0.1600 0.1407 0.1568
Table D.13: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 15% and the angle of incidence equal to 0°.
MetHb SHb
605 620 635 605 620 635
10% 0.2374 0.2868 0.3213 0.2256 0.2601 0.3176
20% 0.2055 0.2356 0.2436 0.1967 0.1971 0.2474
30% 0.1863 0.1970 0.1990 0.1742 0.1660 0.2021
40% 0.1674 0.1716 0.1689 0.1599 0.1428 0.1727
50% 0.1551 0.1539 0.1484 0.1466 0.1318 0.1548
60% 0.1450 0.1423 0.1359 0.1375 0.1227 0.1400
70% 0.1378 0.1322 0.1243 0.1300 0.1156 0.1282
80% 0.1311 0.1251 0.1186 0.1248 0.1108 0.1222
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Table D.14: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 15% and the angle of incidence equal to 15°.
MetHb SHb
605 620 635 605 620 635
10% 0.2355 0.2909 0.3185 0.2234 0.2548 0.3124
20% 0.2042 0.2306 0.2415 0.1967 0.1991 0.2421
30% 0.1853 0.1983 0.1944 0.1734 0.1646 0.2013
40% 0.1679 0.1718 0.1667 0.1589 0.1431 0.1736
50% 0.1557 0.1557 0.1476 0.1468 0.1296 0.1530
60% 0.1456 0.1418 0.1348 0.1369 0.1213 0.1371
70% 0.1377 0.1322 0.1234 0.1302 0.1162 0.1301
80% 0.1326 0.1263 0.1187 0.1265 0.1115 0.1208
Table D.15: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 15% and the angle of incidence equal to 30°.
MetHb SHb
605 620 635 605 620 635
10% 0.2303 0.2812 0.3079 0.2200 0.2486 0.3093
20% 0.2007 0.2263 0.2380 0.1909 0.1948 0.2402
30% 0.1804 0.1956 0.1943 0.1724 0.1646 0.1988
40% 0.1659 0.1691 0.1670 0.1581 0.1454 0.1717
50% 0.1558 0.1537 0.1498 0.1463 0.1308 0.1521
60% 0.1449 0.1409 0.1342 0.1395 0.1224 0.1379
70% 0.1396 0.1333 0.1266 0.1322 0.1166 0.1305
80% 0.1341 0.1267 0.1187 0.1270 0.1153 0.1224
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Table D.16: Reflectance values extracted from dysfunctional curves obtained considering the
blood content of the reticular dermis equal to 15% and the angle of incidence equal to 45°.
MetHb SHb
605 620 635 605 620 635
10% 0.2342 0.2802 0.3070 0.2248 0.2509 0.3040
20% 0.2075 0.2297 0.2367 0.1959 0.1988 0.2420
30% 0.1876 0.1986 0.1984 0.1789 0.1689 0.2014
40% 0.1737 0.1771 0.1712 0.1637 0.1513 0.1770
50% 0.1621 0.1602 0.1562 0.1550 0.1415 0.1602
60% 0.1537 0.1492 0.1427 0.1480 0.1339 0.1470
70% 0.1466 0.1420 0.1339 0.1409 0.1276 0.1380
80% 0.1418 0.1370 0.1290 0.1391 0.1242 0.1326
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Appendix E
Matlab Code for Generating
Swatches and Computing CIELAB
Differences
In this appendix, we present the Matlab [8] code used in the generation of the swatches
and in the computation of the CIELAB difference presented in Figs. 4.5 to 4.8.
1 % Make sure a l l csv f i l e s are p laced one d i r e c t o r y back . cd . .
2 % F i l e s should f o l l o w the naming convent ion as f o l l o w s :
3 % MetHb : sHB 00 mHB 100 VRD 150 Angle 150 . csv
4 % sHB : sHB 10 mHB 15 VRD 150 Angle 150 . csv
5
6 f unc t i on swatch c r ea t i on
7
8 f i l e s = d i r ( ’ . . / ∗ . csv ’ ) ;
9 rgb ar ray = {} ;
10 c i e l a b a r r a y = {} ;
11 f i g u r e (1 ) ; c l f ;
12 f o r f i l e = 1 : s i z e ( f i l e s , 1 )
13 f i g u r e (1 ) ;
14 f igsPerRow = 8 ;
15 subplot ( c e i l ( s i z e ( f i l e s , 1 ) / figsPerRow ) , figsPerRow , f i l e ) ;
16 showRGBFile ( [ ’ . . / ’ , f i l e s ( f i l e ) . name ] ) ;
17 end
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18
19 f unc t i on image = showRGBFile ( f i l ename )
20 rgb = getRGBFile ( f i l ename ) ;
21 image = showRGB( rgb ) ;
22 t i t l e ( f i l ename ) ;
23 outname = s t r s p l i t ( f i l ename , ’ / ’ ) ;
24 outname = outname{end } ;
25 outname = s t r s p l i t ( outname , ’ . ’ ) ;
26 outname = outname {1} ;
27
28 s={ f i l ename } ;
29 r=s t r r e p ( s , ’ . csv ’ , ’ . jpg ’ ) ;
30 r=s t r r e p ( r , ’ . . / ’ , ’ ’ ) ;
31 s t r=s t r j o i n ( r ) ;
32 f i g u r e (2 ) ;
33 c l f ;
34 % This adds black around swatch from the make c i r c l e f i l e .
35 image = make c i r c l e ( image , 300 , 300) ;
36 imshow ( image ) ;
37 imwrite ( image , s t r ) ;
38 end
39
40 f unc t i on image = showRGB( rgb )
41 type = ’ f i n g e r ’ ;
42 cropping = f a l s e ;
43
44 i f ( strcmp ( type , ’ f i n g e r ’ ) )
45 id = ’ ’ ;
46 x = ’ ’ ;
47 % Reads in image f i l e to g ive f i n g e r p r i n t t ex tu re .
48 f i n g e r p r i n t t e x t u r e = double ( imread ( [ ’
f i n g e r p r i n t t e x t u r e ’ , id , ’ . png ’ ] ) ) /255 ;
49 d2f = double ( imread ( [ ’ d2 ’ , x , ’ f ’ , id , ’ . png ’ ] ) ) /255 ;
50 image ( 1 , 1 , : ) = rgb ;
51 image = i m r e s i z e ( image , [ s i z e ( f i n g e r p r i n t t e x t u r e , 1 ) s i z e
( f i n g e r p r i n t t e x t u r e , 2 ) ] ) ;
52 image = image .∗ f i n g e r p r i n t t e x t u r e . / d2f ;
53 o f f s e t = 15 ;
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54 image = image ( ( 1 : 3 5 5 )+o f f s e t , : , : ) ;
55 end
56
57 image = i m r e s i z e ( image , [ 3 0 0 300 ] ) ;
58
59 i f ( cropping )
60 c ropOf f s e t = 0∗ strcmp ( type , ’ f i n g e r ’ ) ;
61 image = image(1+ cropOf f s e t : end/2+cropOf f se t , : , : ) ;
62 end
63
64 imshow ( image ) ;
65 x l a b e l ( num2str ( round ( rgb ∗255) ) ) ;
66 end
67
68 f unc t i on rgb = getRGBFile ( f i l ename )
69 % read in csv data and i n t e r p o l a t e waves 400−700 by 10 ’ s and
r e f l e c t a n c e
70 % with 400 to 700 by 5 ’ s to i n t e r p o l a t e the r e f l e c t a n c e
between .
71 data = getCSVData ( f i l ename ) ;
72 waves = data ( : , 1 ) ;
73 r e f l s = data ( : , 2 ) ;
74 w = 4 0 0 : 5 : 7 0 0 ;
75 r = in t e rp1 ( waves , r e f l s ,w) ;
76 rgb = getRGB(w, r ) ;
77 end
78
79 f unc t i on rgb = getRGB( waves , r e f l s )
80 % s p e i f y the i l l uminant to use . Dayl ight D65 .
81 i l l = ’ d65 ’ ;
82 i f ( strcmp ( i l l , ’ d65 ’ ) )
83 [ wI , i I ] = i l l um inant ( ’ d65 ’ ) ;
84 XYZ2sRGB = makecform ( ’ xyz2srgb ’ , ’ AdaptedWhitePoint ’ ,
whi tepo int ( ’ d65 ’ ) ) ;
85 end
86 % i n t e r p o l a t e i l l uminant with 400−700 by 5 ’ s .
87 i I = in t e rp1 (wI , i I , waves ) ;
88 r e f l s = r e f l s .∗ i I ;
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89 % use c o l o r matching func t i on
90 [ ˜ , xyz ] = spectrumRGB( waves ) ;
91 % use t r a p e z o i d a l r u l e to approximate the area under the
curve .
92 X = trapz ( waves , xyz ( 1 , : , 1 ) .∗ r e f l s ) ;
93 Y = trapz ( waves , xyz ( 1 , : , 2 ) .∗ r e f l s ) ;
94 Z = trapz ( waves , xyz ( 1 , : , 3 ) .∗ r e f l s ) ;
95 % put in to array .
96 XYZ( 1 , : , 1 ) = X;
97 XYZ( 1 , : , 2 ) = Y;
98 XYZ( 1 , : , 3 ) = Z ;
99 % c o l o r match va lue s d iv ided by i n t e g r a t i o n o f waves with
i l lumninant .
100 XYZ = XYZ/( trapz ( waves , i I ) ∗0 .23 ) ;
101 rgb = applycform (XYZ, XYZ2sRGB) ;
102 rgb ar ray = [ rgb array , rgb ∗255 ] ;
103 end
104
105 f unc t i on data = getCSVData ( f i l ename )
106 % read in every other l i n e from csv f i l e s .
107 f = csvread ( f i l ename , 1 , 0 ) ;
108 waves = f ( 1 : 2 : end , 1 ) ;
109 r e f = f ( 1 : 2 : end , 2 ) ;
110 data = waves ;
111 data ( : , 2 ) = r e f ;
112 end
113
114 % Since the re are 16 f i l e s in the d i r e c t o r y (8 SHb and 8 MetHb)
we need to s epe ra t e them .
115 % Since the f i r s t 8 f i l e s that are read in are MetHb f i l e s and
the next 8 are SHb f i l e s
116 % we o f f s e t the index by 8 each on each i t e r a t i o n o f the whi l e
loop in order to output
117 % the RGB va lues o f each swatch to a new csv f i l e as we l l as
determine the
118 % CIELAB d i f f e r e n c e between the SHb and MetHb swatches .
119 n = 1 ;
120 r g b t o f i l e = {} ;
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121 whi le n < 9
122 methb rgb=rgb ar ray {n}
123 s u l f h b r g b=rgb ar ray {n+8}
124
125 methb r=methb rgb (1 , 1 ) ;
126 methb g=methb rgb (1 , 2 ) ;
127 methb b=methb rgb (1 , 3 ) ;
128
129 s u l f h b r=s u l f h b r g b (1 , 1 ) ;
130 s u l f h b g=s u l f h b r g b (1 , 2 ) ;
131 su l f hb b=s u l f h b r g b (1 , 3 ) ;
132
133 f i l e n a m e=s t r ( 1 5 : 2 9 )
134 r g b s t r i n g=s t r c a t ( methb r , methb g , methb b , s u l f h b r ,
su l fhb g , su l f hb b )
135
136 r g b t o f i l e = [ r g b t o f i l e , methb r ] ;
137 r g b t o f i l e = [ r g b t o f i l e , methb g ] ;
138 r g b t o f i l e = [ r g b t o f i l e , methb b ] ;
139 r g b t o f i l e = [ r g b t o f i l e , s u l f h b r ] ;
140 r g b t o f i l e = [ r g b t o f i l e , s u l f h b g ] ;
141 r g b t o f i l e = [ r g b t o f i l e , s u l f hb b ] ;
142
143 f i l e n a m e = s t r c a t ( f i l e name , ’ . csv ’ ) ;
144
145 dlmwrite ( f i l e name , r g b t o f i l e , ’−append ’ )
146
147 f i r s t=rgb ar ray {n}
148 second=rgb ar ray {n + 8}
149
150 r1=f i r s t ( 1 , 1 ) ;
151 g1=f i r s t ( 1 , 2 ) ;
152 b1=f i r s t ( 1 , 3 ) ;
153
154 r1=r1 /255 ;
155 g1=g1 /255 ;
156 b1=b1 /255 ;
157
84
158 rb=second (1 , 1 ) ;
159 gb=second (1 , 2 ) ;
160 bb=second (1 , 3 ) ;
161
162 rb=rb /255 ;
163 gb=gb /255 ;
164 bb=bb /255 ;
165
166 c1 = rgb2lab ( [ r1 g1 b1 ] , ’ whi tepo int ’ , ’ d65 ’ ) ;
167 c3 = rgb2lab ( [ r1 g1 b1 ] ) ;
168 c2 = rgb2lab ( [ rb gb bb ] , ’ whi tepo int ’ , ’ d65 ’ ) ;
169
170 % Fina l s tep in the computation o f CIELAB D i f f e r e n c e s .
171 va l = s q r t ( ( c1 (1 )−c2 (1 ) ) ˆ2 + ( c1 (2 )−c2 (2 ) ) ˆ2 + ( c1 (3 )−c2 (3 ) )
ˆ2)
172 c i e l a b a r r a y = [ c i e l a b a r r a y , va l ] ;
173
174 n = n+1;
175 end
1 % Create black c i r c l e around matlab square swatch .
2 f unc t i on r e s u l t = make c i r c l e ( image , width , he ight )
3 blackout = ones ( width , height , 3) ;
4
5 f o r i = 1 : width
6 f o r j = 1 : he ight
7 % Change l a s t number between 0 and 1 . Lowering adds
black r a i s i n g lowers b lack .
8 %i f s q r t ( ( i − width /2) ˆ2 + ( j − he ight /2) ˆ2) >= (min (
width , he ight ) ∗ 0 . 25 )
9 i f s q r t ( ( i − width /2) ˆ2 + ( j − he ight /2) ˆ2) >= (min (
width , he ight ) )
10 f o r k = 1 : 3
11 blackout ( i , j , k ) = 0 ;
12 end
13 end
14 end
15 end
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16
17 r e s u l t = image .∗ blackout ;
18 end
86
